Clinical trials: Digestive System
Lactose Intolerance
Effect of a Combination of Lactase and L. Salivarius DSM 34078 in Individuals With Lactose Intolerance
The goal of this clinical trial is to test whether a new combination of lactase and bacterial strain (L. Salivarius DSM 34078) can provide longer lasting beneficial effects on lactose digestion and gastrointestinal symptoms…
- Trial name
- NCT06107088
- Testing
- Active 1, Active 2, Active 3
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Novozymes A/S
Solid Tumors
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- DAWN-303 (NCT07522073)
- Testing
- INCB161734, Investigator's choice of chemotherapy
- Where
- 230 sites in United States, Australia and 20 more
- Volunteers
- 588 people
- Sponsor
- Incyte Corporation
Chronic Hepatitis C Infection
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
This study will assess short term safety, antiviral activity and pharmacokinetics (PK) of IDX184 in combination with Peg-interferon (Peg-IFN)/Ribavirin (RBV) in participants with hepatitis C virus (HCV) genotype (GT) 1 infection.
- Trial name
- NCT01011166
- Testing
- IDX184, Peginterferon alfa-2a (Peg-IFN), Ribavirin (RBV)
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
Biliary Tract Cancer
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
To evaluate the preliminary efficacy of KA2507 (an orally active potent and selective HDAC6 inhibitor) in patients with advanced biliary tract cancer (BTC) previously treated with standard of care chemotherapy.
- Trial name
- NCT04186156
- Testing
- KA2507
- Where
- United Kingdom
- Sponsor
- Karus Therapeutics Limited
Hepatitis C, Chronic
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI 201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT00774397
- Testing
- BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 719 people
- Sponsor
- Boehringer Ingelheim
Irritable Bowel Syndrome
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189813
- Testing
- YM060
- Where
- 45 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 691 people
- Sponsor
- Astellas Pharma Inc
Chronic Hepatitis B
Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B
The purpose of this study is to evaluate the safety and efficacy of Entecavir maleate tablets in Chinese patients with hepatitis B
- Trial name
- NCT01926288
- Testing
- Entecavir maleate tablets, blank Baraclude tablets, Blank maleate entecavir tablets
- Where
- 9 sites in China
- Volunteers
- 287 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Intestinal Diseases
Safety and Efficacy of Using NaviAid™ BGE Device (Balloon Guided Endoscopy) For Endoscopic Diagnosis and Treatment
To assess the efficacy of the NaviAid™ BGE Device, while used in conjunction with a standard endoscope for the diagnosis and treatment of the small intestine.
- Trial name
- NCT00398203
- Testing
- NaviAid™ BGE Device
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Smart Medical Systems Ltd.
Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors
A first-in-human evaluation of SYN004, a monoclonal antibody that binds to the EGF receptor on cancer cells. Cetuximab, a marketed antibody, has been shown to be effective by inhibiting the growth of cancer cells thereby…
- Trial name
- SYN004_Ph_1 (NCT02391727)
- Testing
- SYN004
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synermore Biologics Co., Ltd.
Cystic Fibrosis
Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis
The purpose of this research study is to evaluate the safety, tolerability, and efficacy of Interferon gamma-1b (IFN-gamma 1b) when administered by subcutaneous injection over a period of 4 weeks to patients with mild-to-moderate…
- Trial name
- NCT00043342
- Testing
- interferon gamma-1b
- Volunteers
- 51 people
- Sponsor
- InterMune
Advanced Gastric Cancer
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior…
- Trial name
- NCT00519324
- Testing
- Everolimus
- Where
- 8 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
The aim of the study is to confirm efficacy of treatment for 16 and 24 weeks in chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
- Trial name
- NCT01732796
- Testing
- Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127
- Where
- 101 sites in United States, Austria and 12 more
- Volunteers
- 470 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
This study will evaluate the efficacy of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 through 11 years, who are homozygous for the F508del mutation (F/F) or heterozygous for…
- Trial name
- NCT03559062
- Testing
- TEZ/IVA, IVA
- Where
- 27 sites in Australia, Belgium and 7 more
- Volunteers
- 67 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
- Conditions
- Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
- Trial name
- NCT06016088
- Testing
- RSP-1502, Tobramycin inhalation solution
- Where
- 22 sites in United States, Australia
- Volunteers
- 71 people
- Sponsor
- Respirion Pharmaceuticals Pty Ltd
Ulcerative Colitis
An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)
This is a randomised, double-blind, placebo-controlled study to assess the safety and tolerability of multiple ascending doses of BT051 in subjects with moderately to severely active ulcerative colitis.
- Trial name
- SCOUT (NCT05084261)
- Testing
- BT051 200 mg, BT051 800 mg, BT051 3200 mg
- Where
- 6 sites in United States, Georgia and 2 more
- Volunteers
- 24 people
- Sponsor
- Adiso Therapeutics
Hepatitis B
Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns
The primary purpose of this study is to determine whether HepavaxGene TF is non-inferior to the comparator vaccine both at impeding hepatitis B transmission from mothers positive for chronic hepatitis B (Stratum 1) to their…
- Trial name
- NCT01349283
- Testing
- HepavaxGene (thiomersal free), Engerix B
- Where
- China
- Volunteers
- 1,738 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hepatitis C Virus Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir…
- Trial name
- NCT02185794
- Testing
- Voxilaprevir, SOF/VEL
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Absolute Bioavailability of BMS-791325
The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of BMS-791325 relative to 100 µg IV infusion of [13C]-BMS-791325.
- Trial name
- NCT02112110
- Testing
- BMS-791325, [13C]-BMS-791325
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Colonic Diverticulosis
Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study
The purpose of this study is to determine whether mesalamine is effective in the treatment of uncomplicated diverticular disease by reducing the pain.
- Trial name
- NCT01627262
- Testing
- Mesalamine
- Where
- Germany
- Volunteers
- 123 people
- Sponsor
- Dr. Falk Pharma GmbH
Hepatitis A, Hepatitis B
Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine
The purpose of this study is to compare the immunogenicity and safety of three different immunization schedules of inactivated hepatitis A vaccine (HAV) and/ or combined hepatitis A and B vaccine (HABV) in healthy Chinese infants.
- Trial name
- NCT02445703
- Testing
- Inactivated Hepatitis A vaccine (HAV), Combined hepatitis A and hepatitis B vaccine (HABV)
- Where
- China
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.